Increased acidic serine aspartate-rich MEPE-associated motif (ASARM) peptides cause mineralization defects in X-linked hypophosphatemic rickets mice (HYP) and "directly" inhibit renal phosphate uptake in vitro. However, ASARM peptides also bind to phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) and are a physiological substrate for this bone-expressed, phosphateregulating enzyme. We therefore tested the hypothesis that circulating ASARM peptides also "indirectly" contribute to a bone-renal PHEXdependent hypophosphatemia in normal mice. Male mice (n ϭ 5; 12 wk) were fed for 8 wk with a normal phosphorus and vitamin D 3 diet (1% P i diet) or a reduced phosphorus and vitamin D3 diet (0.1% Pi diet). For the final 4 wk, transplantation of mini-osmotic pumps supplied a continuous infusion of either ASARM peptide (5 mg·day Ϫ1 ·kg Ϫ1 ) or vehicle. HYP, autosomal recessive hypophosphatemic rickets (ARHR), and normal mice (no pumps or ASARM infusion; 0.4% P i diet) were used in a separate experiment designed to measure and compare circulating ASARM peptides in disease and health. ASARM treatment decreased serum phosphate concentration and renal phosphate cotransporter (NPT2A) mRNA with the 1% P i diet. This was accompanied by a twofold increase in serum ASARM and 1,25-dihydroxy vitamin D 3 [1,25 (OH)2D3] levels without changes in parathyroid hormone. For both diets, ASARM-treated mice showed significant increases in serum fibroblast growth factor 23 (FGF23; ϩ50%) and reduced serum osteocalcin (Ϫ30%) and osteopontin (Ϫ25%). Circulating ASARM peptides showed a significant inverse correlation with serum P i and a significant positive correlation with fractional excretion of phosphate. We conclude that constitutive overexpression of ASARM peptides plays a "component" PHEXindependent part in the HYP and ARHR hypophosphatemia. In contrast, with wild-type mice, ASARM peptides likely play a bone PHEX-dependent role in renal phosphate regulation and FGF23 expression. They may also coordinate FGF23 expression by competitively modulating PHEX/DMP1 interactions and thus bone-renal mineral regulation. matrix extracellular phosphoglycoprotein; dentin matrix protein-1; mineralization; osteomalacia; SIBLING proteins; fibroblast growth factor 23; X-linked hypophosphatemic rickets; 1,25 dihydroxy vitamin D3
dentin matrix protein-1 (DMP1), osteopontin (OPN), bone sialoprotein, enamelin, dentin sialo phosphoprotein, and statherin (19, 50) . Key features of several SIBLINGs are an acidic serine aspartate-rich MEPE-associated motif (ASARM motif) (50) involved in bone and teeth mineralization (49, 50) . Among these proteins, MEPE was cloned from a tumor resected from a patient with tumor-induced osteomalacia (TIO) and hypophosphatemia (50) . Increased expression of MEPE occurs in TIO, X-linked hypophosphatemic rickets (HYP), and autosomal recessive hypophosphatemic rickets (ARHR), diseases with overlapping pathophysiologies (3, 9, 22, 31, 37, 46, 48, 65, 66) . Mutations in DMP1, a SIBLING protein closely related to MEPE, are responsible for ARHR (18, 35) . The COOH-terminal end of both MEPE and DMP1 contains the ASARM-like motif and this corresponds to the last 23 amino acid residues of MEPE (37, 50) . In HYP bone, proteolytic degradation of MEPE and DMP1 releases protease-resistant phosphorylated ASARM peptides into bone and circulation (49) . We previously showed in vitro and in vivo that ASARM peptide is responsible for inhibition of mineralization in HYP osteoblasts (37) . We also showed that PHEX, a membrane protein present in osteocytes and osteoblasts, is able to bind to MEPE via the ASARM motif (31, 37, 51) . This interaction could prevent proteolysis of MEPE and release of proteaseresistant ASARM peptide in vivo (20, 49, 51) . Also, PHEX binds to free ASARM peptide neutralizing its activity by sequestration and hydrolysis (2, 10, 31, 37, 51) . In HYP, defective PHEX (null activity) is accompanied by increased activities from other bone proteases (16, (37) (38) (39) 48) and increased MEPE expression (4, 9, 30, 37, 48, 49, 66) . This causes the release of excessive amounts of protease-resistant ASARM peptides from MEPE and likely DMP1 (4, 9, 13, 30, 37, 48, 49, 66) . These peptides are candidates for the growth and mineralization defects in vivo (37) . Specifically, ASARM peptides are potent inhibitors of mineralization (2, 7, 13, 31, 37, 51, 52) and administration in vitro induces increased expression of fibroblast growth factor 23 (FGF23), a potent phosphatonin (31, 37) . ASARM peptides likely induce increased FGF23 expression by competing with other PHEX substrates and/or disrupting PHEX activity (2, 10, 31, 37, 51) . It remains to be determined how loss of PHEX activity induces increased FGF23 expression.
Although the ASARM model is compelling, specific in vivo questions remain. For example, several studies confirm fulllength MEPE inhibits intestinal/renal phosphate transport and mineralization in vivo and in vitro (14, 36, 49, 52, 56) . These studies consist of bolus injections or direct perfusion in rats and mice using recombinant MEPE protein. In vitro studies using ASARM peptides show similar results (1, 2, 31, 37, 48, 51, 52, 56), but no long-term in vivo infusion studies are reported. We hypothesize circulating ASARM peptides are responsible for, at least in part, "PHEX-independent" hypophosphatemia in HYP and ARHR mice in vivo. Also, since ASARM administration binds/disrupts PHEX activity, reduces PHEX expression, and increases FGF23 expression in wild-type bone cultures (2, 29, 37, 51), we further hypothesize ASARM peptides also induce hypophosphatemia "PHEX dependently" in vivo.
To this end, we administered ASARM peptide using osmotic pump infusion for a 4-wk period to wild-type C57Bl6 mice and measured circulating ASARM peptide levels. Since HYP and ARHR mice have hypophosphatemia and low 1,25 (OH) 2 D 3 , we fed normal mice either a normal diet or a diet reduced in phosphorus and vitamin D content.
MATERIALS AND METHODS

Animals and peptides.
Mice (C57BL/6) were housed at the University of Kansas Medical Center under the supervision of the Department of Laboratory Animal Resources. The policies and procedures of the animal laboratory are in accordance with those detailed in the Guide for the Care and Use of Laboratory Animals published by the US Department of Health and Human Services. Procedural protocols were approved by the University of Kansas Institutional Animal Care and Use Committee. Twenty 12-wk-old male C57B/L6 wild-type mice were used (n ϭ 5/group) for the Alzet pump infusion study with 30 control untreated mice (without pumps or infusion). A total of 15 control mice (no pumps or treatment) were used for the 0.1% P i diet and 1% Pi diets, respectively (n ϭ 15). The pump-treated mice consisted of four groups (n ϭ 5) as follows: 1) 1% Pi diet vehicle (V), 2) 1% Pi diet ASARM infused, 3) 0.1% Pi diet V infused, and 4) 0.1% Pi diet ASARM infused. Animals were individually housed and fed ad libitum either a phosphate and vitamin D3-deplete diet (0.1% P i) or a phosphate and vitamin D3-replete diet (1% Pi) for 2 mo. The 1% Pi diet contained 1% phosphorus and 2.4 IU/g vitamin D3 diet (Harlan Teklad Rodent Diet 8604, Indianapolis, IN), and the 0.1% Pi diet contained 0.1% of phosphorus and 1 IU/g vitamin D3 diet (Test Diet AIN-93M, Richmond, IN). During the last month of the respective diets, mice were also infused using Alzet osmotic pumps (Durect, Cupertino, CA) with ASARM peptide (5 mg·day
) or V (HEPES-buffered saline). Untreated C57B/L6 12-wk-old male mice (without Alzet pumps or ASARM infusion; n ϭ 15) were also included as additional controls. ASARM peptide [NH2-RDDSSESSDSGS(PO 3H2)SS(PO3H2)ES-(PO3H2)DGD-OH] was synthesized using standard techniques and purchased from neo-MPS Biosystems (Multiple Peptide Systems, San Diego, CA) as described previously (37, 51) . Peptide purity was greater than 80% via HPLC, ion exchange, and also mass spectrometry. HYP (66) and ARHR mice (DMP1 null) (18) were age and gender matched (male; 12 wk). Sera were collected as described for the wild-type mice. HYP mice, DMP1-null mice (ARHR), and wildtype littermates (C5B/L6, backgrounds, 6 wk) were compared separately to the Alzet pump and control mice group and were not treated with pumps or ASARM peptides. Also, these mice (HYP, ARHR, and wild-type) were fed a 0.4% P i diet (Lab Diet no. 5001; PMI LabDiet, St. Louis, MO) since this diet was optimal for mutant mice viability.
Serum and urine measurements. Blood samples were collected in separator tubes and urine was collected overnight in metabolic cages. Osteocalcin (Mouse Osteocalcin EIA Kit; BTI, Stoughton, MA), alkaline phosphatase (Liquid Alkaline Phosphatase; Pointe Scientific, Canton, MI), 1,25 (OH)2D3 (IDS, Fountain Hills, AZ), and FGF23 (Kainos Laboratories, Tokyo, Japan) were measured on serum samples. Inorganic phosphorus, calcium, creatinine (Pointe Scientific), and OPN (Quantikine Mouse Osteopontin; R&D Systems, Minneapolis, MN) levels were assessed both in serum and urine. A competitive ELISA kit was used for the ASARM peptide measurement as previously published for serum and urine samples (9, 48, 66) .
Statistical analysis. Statistical analysis was performed using statistical software STATISTICA (StatSoft, Tulsa, OK) or PRISM5 (GraphPad Software, La Jolla, CA). Differences between groups were initially analyzed by two-way ANOVA. When F values for a given variable were found to be significant, the sequentially rejecting Bonferroni-Holm test was subsequently performed using the Holm's adjusted P values. Results were considered to be significantly different at P Ͻ 0.05.
RESULTS
ASARM peptide is phosphaturic, correlates with serum P i , and decreases NPT2a. Creatinine clearance, serum creatinine, albumin/creatinine ratio, urinary and serum K ϩ , urinary and serum Na ϩ , pH, and blood urea nitrogen were not significantly different between age-and sex-matched V, control, and ASARM pump mice (not shown). In contrast, animals on the 1% P i diet treated with ASARM peptide had a 2.2-fold increased fractional excretion of phosphate (FEP; P Ͻ 0.05) and decreased serum phosphate (Ϫ24%; P Ͻ 0.05) compared with V and controls (Fig. 1, A and B) . The low-phosphorus diet mice (both groups) were all hypophosphatemic relative to mice fed Fig. 1 . Acidic serine aspartate-rich MEPE-associated motif (ASARM) peptides induce hypophosphatemia, increase the fractional excretion of phosphate (FEP), and decrease expression of NPT2a mRNA. FEP (%; A) and serum Pi (mg/dl; B) in mice (n ϭ 5) fed the 1% Pi diet and the 0.1% Pi diet as indicated on the x-axis. For both A and B, diagonally striped columns represent control mice without osmotic pumps, filled columns represent osmotic pump "vehicle"-infused mice and checked columns represent osmotic pump "ASARM peptide"-infused mice. The significant differences in FEP and serum Pi metrics between ASARM-treated and vehicle-treated mice on both 1% Pi and 0.1% Pi diets are numbered on the graph (P value; 1-way ANOVA with NewmanKeuls multiple comparison test). P values of Ͻ0.05 are considered significant and are also highlighted with *. P values Ͻ0.0001 are highlighted with ***. NS, nonsignificant. Arrows highlight the columns compared by 1-way ANOVA and Newman-Keuls posttest. Broken lines highlight cross comparisons for more than one column where the significance or nonsignificance computation is identical. Finally, 2-way ANOVA analyses for FEP and serum Pi showed significant ASARM treatment and diet-dependent differences with low statistical interactivity [FEP ϭ (P Ͻ 0.0001 for ASARM and P Ͻ 0.0001 for diet) and serum-Pi ϭ (P ϭ 0.03 for ASARM and P ϭ 0.01 for diet)]. C: RT-qPCR analysis of renal Na ϩ -dependent phosphate cotransporter expression (NPT2A; measured as described previously in Refs. 13, 37). the 1% P i . Also, the ASARM-treated 0.1% P i group had increased phosphaturia compared with the 0.1% P i V and control mice (Fig. 1B) . The hypophosphatemia and renal phosphate leak was mirrored by a significant decreased expression of NPT2a mRNA (Fig. 1C) . Consistent with this finding, a significant inverse correlation between serum P i and serum ASARM peptides occurred with V mice and control mice. The inverse correlation between serum P i and serum ASARM holds for different ages and diets (Fig. 2, A and B) . In agreement with these observations, an opposite positive correlation between urinary ASARM peptides and FEP occurred with V and control mice (Fig. 2C) . In contrast, no significant correlations were observed between serum P i and serum ASARM in mice treated with synthetic ASARM peptides (osmotic pumps, both diets; Fig. 2D ), HYP mice, or DMP1 mice (data not shown). This was despite the hypophosphatemia and increased FEP relative to V and control groups. The lack of correlation in ASARMtreated wild-type mice is likely due to ASARM supersaturation and a threshold effect. In HYP mice and DMP1-null mice, a more complex mechanism is likely due to the constitutive overexpression of FGF23 and mutations in PHEX and DMP1, respectively. This interpretation is congruent with the strong correlations between ASARM peptides (serum and urine) and serum P i or FEP in normal mice and V mice on all diets. Specifically, the untreated normal mice have lower subthreshold levels of endogenous ASARM peptides.
Dietary P i and 1,25 (OH) 2 D 3 alter serum and urinary ASARM peptide levels. On both diets, ASARM peptide-treated mice displayed a greater than twofold increase in serum ASARM levels (P Ͻ 0.05) compared with the V-treated animals (Fig. 3A) . Also, a significant 0.5-fold increase in serum ASARM peptides occurred with both the ASARM-treated and V mice fed the 0.1% P i diet relative to matched groups on the 1% P i diet (Fig. 3A) . A significant decrease in urinary ASARM peptides (corrected for creatinine) occurred with V-treated mice fed the 0.1% P i diet. In contrast, urinary ASARM peptide levels remained the same for both diets with ASARM-treated mice (Fig. 3B) . Thus, on the 0.1% P i diet, urinary ASARM levels were significantly higher with ASARM-treated mice relative to V-treated mice. Of note, with control mice (without osmotic pumps) and V mice (with osmotic pumps) on both diets, an inverse correlation between serum ASARM and urinary ASARM peptides occurs (Fig. 3, C, D , and E). However, the correlation is weaker with mice on the 0.1% P i diet. In contrast, ASARM-treated mice showed a nonsignificant trend toward a positive correlation between serum ASARM and urinary ASARM (Fig. 3F ). In conclusion, these data demonstrate ASARM peptide levels are subject to dietary P i and vitamin D3.
Increased ASARM peptides in HYP and ARHR correlate with phenotype. Serum P i levels of DMP1 Ϫ/Ϫ null mice (ARHR) were significantly higher than HYP mice and significantly lower than wild-type mice fed the same diet. The converse was true for serum ASARM peptide levels. Indeed, an inverse correlation between serum P i and serum ASARM peptides mirrored the phenotypic severity of the hypophosphatemia (Fig. 4, A, B, and C) .
ASARM regulates the 1,25(OH) 2 D 3 /FGF23/PTH system. ASARM treatment led to a significant twofold increase in 1,25 (OH) 2 D 3 serum levels in mice fed the 1% P i diet. In contrast, there were no significant differences in serum 1,25 (OH) 2 D 3 between both ASARM-treated and V groups on the lowphosphate diet (Fig. 5A) . However, V and ASARM-treated mice fed the 0.1% P i diet had a significant two-and fourfold decrease in 1,25 (OH) 2 D 3 serum levels, respectively (relative to 1% P i diet-fed mice). This was because of the severely decreased dietary vitamin D3 composition of the 0.1% P i diet. In accord with the low dietary vitamin D3, a twofold increase (P Ͻ 0.05) in serum parathyroid hormone (PTH) levels for V-treated animals occurred with the 0.1% P i diet (Fig. 5B) . In contrast, ASARM-treated animals retained uniform PTH levels on both diets. Increased phosphorus excretion was concordant with increased FGF23 serum levels in both ASARM-treated groups compared with their diet-matched V groups (P Ͻ 0.05; Fig. 5C ). A marked decrease in FGF23 levels occurred in both 0.1% P i diet groups compared with the 1% P i diet-fed mice. Also, for both diets, a significant increase in serum FGF23 levels occurred with ASARM-treated vs. V mice. The increase was more marked with the 1% P i diet and two-way ANOVA analysis showed a significant ASARM peptide-dependent effect on FGF23 levels (P ϭ 0.0037). FGF23 levels in HYP and DMP1-null mice were increased 10-fold as reported previously (18, 66) , data not shown.
Infused ASARM peptide suppresses urinary serum and urine OPN. Since OPN is a SIBLING protein with an ASARM motif with strong links to bone-renal mineral homeostasis, we measured expression of this protein (5, 47). For the 1% P i diet, a marked significant decrease in urinary and serum OPN levels occurred with ASARM-treated animals relative to control and V mice (Fig. 5, D and E) . In contrast, no significant differences occurred with ASARM-treated mice fed the 0.1% P i diet relative to control and V mice. Of note, OPN levels (sera and urine) were decreased significantly in V-treated and control animals fed the 0.1% P i diet relative to the 1% P i diet (Fig. 5,  D and E) . This diet-associated decrease did not occur with ASARM-treated mice (only with the wild-type mice). Specifically, the relative OPN levels on 1% P i and 0.1% P i diets remained unchanged with ASARM-treated mice (Fig. 5, D  and E) .
DISCUSSION
The ASARM motif is released as a small protease-resistant ASARM peptide following degradation of MEPE and other SIBLINGs (e.g., DMP1) by osteoblastic proteases (9, 37, 48, 49) . The abundance of these peptides in hypophosphatemic and bone mineralization disorders (8, 9, 48, 66) suggests they play a key role in phosphate and bone-mineral homeostasis. To our knowledge, this is the first study establishing ASARM as a phosphaturic peptide that induces hypophosphatemia in vivo. Fig. 4 . ASARM peptides correlate inversely with serum Pi and degree of phenotypic severity (hypophosphatemia) displayed in X-linked hypophosphatemic rickets (HYP) and dentin matrix protein-1 (DMP1)-null mice. A: serum Pi levels in age-and sex-matched (male) HYP, DMP-null, and normal mice on the 0.4% Pi diet. B: endogenous serum ASARM peptide levels in ageand sex-matched (male) HYP, DMP-null, and normal mice on the 0.4% Pi diet. For both A and B, filled columns represent HYP mice, vertical striped columns represent DMP1-null mice, and checked columns normal mice. Significant differences between columns are numbered on the graph (P value; 1-way ANOVA with Newman-Keuls multiple comparison test). Specifically, P values of Ͻ0.05 are considered significant and are also highlighted with *. Arrows highlight the columns compared by 1-way ANOVA and Newman-Keuls posttest. C: correlation between phenotypic hypophosphatemic severity and circulating serum ASARM peptides in wild-type, HYP, and DMP1-null mice (r ϭ Ϫ0.9912, R 2 ϭ 0.9824, P Ͻ 0.05). Control mice are normal mice without osmotic pumps, vehicle, or synthetic ASARM peptide infusion. Note, all mice are male 19-wk and C57BL/6 strains. KO, knockout. Fig. 3 . Dietary Pi and vitamin D3 alter serum and urinary ASARM peptide levels in vehicle mice and mice infused with ASARM peptides. Sera (A) and urinary ASARM peptides (B) in mice (n ϭ 5) fed the 1% Pi diet (normal phosphate and vitamin D replete) and the 0.1% Pi diet (low phosphate and vitamin D deficient). For both A and B, filled columns represent osmotic pump vehicle-infused mice and checked columns represent osmotic pump ASARM peptide-infused mice. The significant differences in FEP and serum Pi metrics between ASARM-treated and vehicle-treated mice on both 1% Pi and 0.1% Pi diets are numbered on the graph (P value; 1-way ANOVA with NewmanKeuls multiple comparison test). P values of Ͻ0.05 are considered significant and are also highlighted with *. Arrows highlight the columns compared with 1-way ANOVA and Newman-Keuls posttest. Broken lines highlight cross comparisons for more than one column where the significance or nonsignificance computation is identical. With 2-way ANOVA, significant ASARM treatment and diet-dependent differences with low statistical interactivity occurred (P Ͻ 0.0001 for ASARM and P Ͻ 0.0001 for diet). C: urine ASARM peptides correlate negatively with serum ASARM peptides in control mice fed the 1% Pi diet (r ϭ Ϫ0.7607, R 2 ϭ 0.5786, P ϭ 0.0002). D: urinary ASARM peptides correlate inversely with serum ASARM peptides in control mice fed the 0.1% Pi diet (r ϭ Ϫ0.7275, R 2 ϭ 0.5292, P ϭ 0.04). E: urinary ASARM peptides correlate negatively with serum ASARM peptides in vehicle mice with osmotic pumps transplants (r ϭ Ϫ0.6842, R 2 ϭ 0.4681, P ϭ 0.04). Our study shows a significant decrease (Ϫ97%; P Ͻ 0.05) in NPT2A renal phosphate transporter mRNA expression is likely responsible for the lowered serum P i . However, altered NPT2c expression may also be involved since both NPT2a and NPT2c renal phosphate transporters are decreased in several familial and oncogenic hypophosphatemic bone mineralization disorders including HYP, ADHR, ARHR, and TIO (27, 45, 49, 59) . As reported previously, we found increased serum ASARM peptides in mice with HYP relative to normal mice (2, 9, 31, 37, 48, 66) . For the first time, we also confirm serum ASARM peptide epitopes are increased in mice with autosomal recessive hypophosphatemic rickets (ARHR or DMP1-null mice; Fig. 4) . Intriguingly, the ARHR hypophosphatemia was intermediate to wild-type and HYP and this correlated with circulating ASARM peptide levels. Thus, we provide further evidence that shows ASARM peptides play a major role in the bone-renal pathophysiology of familial and oncogenic hypophosphatemic disorders. Fig. 7) . The PHEX-DMP1 binding initiates a signaling pathway that reduces FGF23 expression. Note that in support of this, in XLH and ARHR, mutations in "PHEX or DMP1" result in hypophosphatemia through increased FGF23 expression and stability (overlapping pathophysiologies) (18, 24, 35) . Also, PHEX binds with high affinity and specificity to ASARM peptides or ASARM protein motifs (MEPE, DMP1, and osteopontin derived) and MEPE protein (1, 2, 37, 51) . PHEX cleaves ASARM peptides, the only known physiological substrate for PHEX (1, 2, 10, 37, 51) . Also, SIBLINGs (like DMP1) activate PHEX-related Zn matrix metalloproteinases via their binding interactions (17, 25) . DMP1 for example binds and activates a PHEX-related Zn matrix metalloproteinase 9 (MMP9) (17) . Finally, the in vitro addition of recombinant DMP1 to UMR-106 cells causes a dose-dependent decrease in FGF23 expression (mRNA and protein) (54) . ASARM peptides are proposed to competitively displace the DMP1-PHEX complex in "normal mice" by forming a high-affinity/specificity PHEX-ASARM complex (37, 51) that is slowly hydrolyzed (low Kcat/Km) by PHEX (1, 2, 10) . 2) This causes an upregulation of FGF23. 3) Increased FGF23 expression leads to reduced 1,25 vitamin D3, reduced NPT2a expression, and hypophosphatemia. The competitive displacement of DMP1 by ASARM peptides provides an additional "bone" fine tuning of FGF23 and renal phosphate mineral homeostasis. B: direct pathophysiological ASARM pathway that is independent of FGF23, PHEX, and DMP1 is proposed to occur in familial HYP, ARHR, and ADHR. For example, in XLH and ARHR, expression of MEPE and several bone proteases including cathepsins, ECEL1/DINE, and NEP are markedly increased (37-39, 48, 55) resulting in excess ASARM peptide production and inhibition of mineralization (2, 9, 37, 48, 66) . In these diseases, specific cleavage of MEPE and/or other bone SIBLING proteins (DSPP, OPN, DMP1, etc.) generates an excess of free protease-resistant ASARM peptides (37, 48) . ASARM peptides are acidic, highly charged, with low Pis and are extraordinarily resistant to a wide range of proteases and have physicochemical similarities to bisphosphonates, phosphonoformic acid (PFA), and phosphonoacetic acid (PAA). Also, they share biological properties in vivo and in vitro with bisphosphonates, PFA, and PAA in that they all inhibit mineralization and interfere with renal phosphate handling and vitamin D metabolism (6, 28,  32-34, 40 -42, 57, 58, 60, 61, 63) . Much work remains to be done to confirm the proposed speculative model presented in the above scheme. Mice were fed the 1% Pi diet or the 0.1% Pi diet as labeled on the x-axis (n ϭ 5; ASARM, vehicle, and control). Diagonally striped columns represent control mice without osmotic pumps, filled columns represent osmotic pump vehicle-infused mice, and checked columns represent osmotic pump ASARM peptide-infused mice. The significant differences in metrics between ASARMtreated and vehicle-treated mice on both 1% Pi and 0.1% Pi diets are numbered on the graph (P value; 1-way ANOVA with Newman-Keuls multiple comparison test). P values of Ͻ0.05 are considered significant and are also highlighted with *. Arrows highlight the columns compared by 1-way ANOVA and Newman-Keuls posttest. Broken lines highlight cross comparisons for more than one column where the significance or nonsignificance computation is identical. Finally, for all metrics, 2-way ANOVA confirmed significant ASARM treatment-dependent differences between mice and control or vehicle mice (P Ͻ 0.05). For control mice or vehicle mice, 2-way ANOVA analysis showed significant diet-influenced changes for all metrics (P Ͻ 0.05). For ASARM-treated mice, 2-way ANOVA showed significant diet-influenced changes for all metrics (P Ͻ 0.05) except for serum PTH and serum/urine OPN. Note, all mice are male 19-wk and C57BL/6 strains. Control mice are normal mice without osmotic pumps, vehicle, or synthetic ASARM peptide infusion.
In this study, ASARM-induced hypophosphatemia in wildtype mice on a normal diet (1% P i ) was accompanied by an increase in serum 1,25 (OH) 2 D 3 . This increase in 1,25 (OH) 2 D 3 is consistent with our previous in vivo findings following bolus injections of full-length recombinant MEPE in wild-type mice (52) . Also, the vitamin D receptor-null mouse has increased MEPE expression (44) , and 1,25 (OH) 2 D 3 suppresses MEPE expression in vitro (3) . Of note, the increase in ASARM peptide levels observed in the V mice on a combined low-phosphorus and low-vitamin D3 diet (0.1% P i ) suggests that P i and 1,25 (OH) 2 D 3 are potent inhibitors of ASARM production under physiological conditions. Since ASARM peptides are derived in part by cleavage of MEPE by cathepsins and other osteoblastic proteases (8 -10, 16, 37-39, 48, 49) , this increase was likely sourced from the endogenous biological pool of peptides.
The ASARM-induced, increased serum 1,25 (OH) 2 D 3 contrasted with the inappropriately normal levels of 1,25 (OH) 2 D 3 found in HYP mice with pathologically increased endogenous ASARM peptides (15) . However, ASARM treatment of normal mice (both diets) mirrored the increased FGF23 reported for HYP mice (9, 31, 37, 48, 66) and was uniform with our previous ASARM peptide in vitro findings (31, 37) . Notably, the increased serum FGF23 is consistent with the known feedback mechanism designed to suppress inappropriate increases in serum 1,25 (OH) 2 D 3 (53) . In contrast, PTH levels remained unchanged in the ASARM peptide-treated mice on the normal 1% P i diet. This was likely also due to the ASARMmediated increase in serum 1,25 (OH) 2 D 3 . The ASARMinduced hypophosphatemia [despite the increased serum 1,25(OH) 2 D 3 ] is evidence for a direct suppression of renal P i transport due to increased FGF23. Indeed, several studies report FGF23 interacts with KLOTHO to directly suppress renal NPT2A expression in the brush border of renal proximal convoluted tubules (45) . Likewise, ASARM peptides (in vitro) and MEPE (in vivo and in vitro) directly inhibit Na-dependent P i uptake in renal cells (14, 36, 49, 51, 52, 56) .
ASARM peptides bind with high specificity to PHEX and some of the ASARM peptide biological effects are mediated through a PHEX-ASARM interaction that includes regulation of FGF23 expression (31, 37, 51) . However, although the evidence presented from our studies and others show compellingly ASARM peptides affect phosphate regulation indirectly through a PHEX/FGF23/DMP1 pathway, there is also evidence of direct inhibition. Specifically, ASARM peptides and recombinant MEPE directly inhibit P i uptake in renal cell cultures and recombinant MEPE inhibits P i uptake in renal micropuncture experiments (14, 36, 48, 51, 52, 56, 62) . The direct inhibition is likely initiated by physicochemical mechanisms similar to that described for etidronate and foscarnet Fig. 7 . DMP1 ASARM region (COOH residues 464 to 478) shows homology to ASARM peptide and likely competes for PHEX binding. Flanking this region is a sequence also conserved in DMP1 (minfostin motif) and mutations here result in ARHR (18, 26) . Since MEPE and osteopontin ASARM peptides bind specifically to PHEX (1, 2, 10, 37, 51), we would propose the DMP1 ASARM motif also interacts with PHEX protein. Thus, free ASARM peptides likely compete with PHEX for DMP1 binding as described in Fig. 7 . The ASARM region (DMP1 and MEPE) consists of serine residues interspersed with acidic aspartate (D) and glutamic acid (E) residues. The serine residues are phosphorylated and the SXSSSE(S/D) conserved sequence of DMP1 and ASARM contains identical consensus casein-kinase II phosphorylation sites. Of relevance, a highly conserved GD sequence occurs in both MEPE-ASARM peptide and DMP1-ASARM motif as highlighted in the alignment. The GD sequence resides in the DMP1 minfostin region and likely plays an important role in PHEX binding. A DMP1 frameshift mutation in this minfostin region that alters the COOH-terminal sequence at position 498 following residues LTVDA (with loss of the GD domain and an increase of 13 residues) results in ARHR (18, 26) .
(acidic, phosphorylated low-P i compounds) (6, 28, 32-34, 40 -42, 57, 58, 60, 61, 63) . Although the "indirect" ASARM (PHEX/FGF23/NPT2a) pathway mechanism is now well-described, the "direct" pathophysiological pathway requires further investigation. As discussed in previous papers, the ASARM peptide can somewhat be described as a biological bisphosphonate (48, 49, 51, 52) .
Since MEPE ASARM peptides are mineralization inhibitors (2, 7, 13, 31, 37, 51, 52) , their presence in urine may well help suppress renal calcification (13) . Indeed, we recently showed mice overexpressing MEPE contained increased urinary ASARM peptides and were resistant to diet-induced renal calcification (13) . Also, OPN (a related SIBLING protein) has been implicated as a component player in the exquisitely complex multistep process of renal stone formation (11-13, 21, 23, 43, 64) . Remarkably, our data show synthetic ASARM peptides suppress significantly serum/urine OPN levels (protein) in mice fed the 1% P i diet. This is consistent with our earlier studies with MEPE transgenic mice that showed marked suppression of renal calcification with increased urinary ASARM peptides and altered OPN (13) . More studies are required, however, to confirm a direct mechanistic role for OPN and acidic ASARM peptides. Figure 6 illustrates a scheme that proposes a physiological role for ASARM peptides and Fig. 7 shows the extended cross species homologies of the DMP1 and MEPE ASARM regions. Specifically, FGF23 expression and processing are regulated by competitive displacement of the DMP1-PHEX complex by free ASARM peptides. A feedback regulatory loop involving FGF23, 1,25(OH) 2 D 3 , ASARM peptides, and PHEX orchestrates this pathway as explained in Fig. 6 . Thus, we propose a novel pathway linking bone mineralization, bone turnover, and phosphate requirement across a bone-renal axis. More work is needed to confirm this pathway particularly the proposed interactions between DMP1 and PHEX through the DMP1-ASARM motif. Compelling support for the model is provided by the demonstration that PHEX and DMP1 mutations lead to identical pathophysiologies (18, 24, 35) and PHEX binds/ hydrolyzes ASARM peptides (1, 2, 10, 37, 51) . To date, ASARM peptides are the only known physiological substrate for PHEX (1, 2, 10, 37, 48, 51) .
To conclude, our study shows for the first time ASARM peptide(s) from MEPE and likely other SIBLING proteins (DMP1, for example) are phosphaturic agents in vivo. Also, these peptides likely play an indirect PHEX-dependent in vivo regulatory link between DMP1, FGF23, and bone-renal mineral regulation in normal mice. Contrasting with normal mice, HYP and ARHR mice have defective PHEX and DMP1, respectively. Because of this, there is no PHEX-DMP1 interaction and FGF23 is therefore constitutively overexpressed. Also, the FGF23 overexpression is independent of an upstream ASARM-regulated PHEX/DMP1 interaction. However, both mutant mice (HYP and ARHR) overexpress ASARM peptides due to abnormal bone protease expression (16, (37) (38) (39) 48) and increased MEPE expression (4, 9, 30, 37, 48, 49, 66) . In this abnormal context, ASARM peptides likely play a direct but component "PHEX-independent" part in the hypophosphatemic pathology. Specifically, in HYP and ARHR, FGF23 is the chief hypophosphatemic stimulus and ASARM peptides exacerbate the renal phosphate leak by virtue of their overabundance and intrinsic, hypophosphatemic, physicochemical properties.
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